Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Fabre

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Plos One|November 7, 2024
Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinomaJeremy Slomka, Hugo Berthou, Audrey Mansuet-Lupo, et al.
Pathology Oncology Research : POR|November 8, 2017
Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2Antoine Legras, Hélène Roussel, Giuseppe Mangiameli, et al.
Cancers|October 23, 2021
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and ChemotherapySamy Chelabi, Xavier Mignard, Karen Leroy, et al.
Plos One|January 25, 2012
TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinomaKarine Pallier, Anatole Cessot, Jean-Francois Côté, et al.
International Journal of Cancer|October 11, 2012
Recurrent inactivating mutations of ARID2 in non-small cell lung carcinomaGilles Manceau, Eric Letouzé, Cécile Guichard, et al.
BMC Cancer|May 13, 2022
Prognostic value of CD4+ T lymphopenia in non-small cell lung CancerGuillaume Eberst, Dewi Vernerey, Caroline Laheurte, et al.
Clinical Therapeutics|July 8, 2020
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older PatientsEvelina Cardoso, Monia Guidi, Nihel Khoudour, et al.
Translational Lung Cancer Research|October 21, 2024
Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinomaGary Birsen, Valérie Gounant, Nicolas Girard, et al.
Interactive Cardiovascular and Thoracic Surgery|March 14, 2015
A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objectiveFabrice Barlesi, Christos Chouaid, Jacky Crequit, et al.
Clinical Nutrition ESPEN|September 7, 2024
Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 studyManuela Tiako Meyo, Pascaline Boudou-Rouquette, Jennifer Arrondeau, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Plos One|November 7, 2024
Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinomaJeremy Slomka, Hugo Berthou, Audrey Mansuet-Lupo, et al.
Pathology Oncology Research : POR|November 8, 2017
Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2Antoine Legras, Hélène Roussel, Giuseppe Mangiameli, et al.
Cancers|October 23, 2021
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and ChemotherapySamy Chelabi, Xavier Mignard, Karen Leroy, et al.
Plos One|January 25, 2012
TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinomaKarine Pallier, Anatole Cessot, Jean-Francois Côté, et al.
International Journal of Cancer|October 11, 2012
Recurrent inactivating mutations of ARID2 in non-small cell lung carcinomaGilles Manceau, Eric Letouzé, Cécile Guichard, et al.
BMC Cancer|May 13, 2022
Prognostic value of CD4+ T lymphopenia in non-small cell lung CancerGuillaume Eberst, Dewi Vernerey, Caroline Laheurte, et al.
Clinical Therapeutics|July 8, 2020
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older PatientsEvelina Cardoso, Monia Guidi, Nihel Khoudour, et al.
Translational Lung Cancer Research|October 21, 2024
Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinomaGary Birsen, Valérie Gounant, Nicolas Girard, et al.
Interactive Cardiovascular and Thoracic Surgery|March 14, 2015
A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objectiveFabrice Barlesi, Christos Chouaid, Jacky Crequit, et al.
Clinical Nutrition ESPEN|September 7, 2024
Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 studyManuela Tiako Meyo, Pascaline Boudou-Rouquette, Jennifer Arrondeau, et al.
Pageof 8